SecBot SecBot
PRESS-RELEASE ·Filed Nov 3, 2026

SYRE

Spyre Therapeutics, Inc.
BEARISH
Impact 5/10
Horizonmonths Processed13d 9h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss and widening loss are tempered by a strong cash runway and positive pipeline data. Watch for SKYLINE Part B topline results in Q3 2027 and initiation of pivotal HS studies in 2027 as key catalysts.

DirectionBearish
Confidencehigh
Horizonmonths

Drugs in focus

SYRE drug pipeline →

SPY002

▲ Bullish Named in this press release
Impact
Phase
Phase 2
Time to market
SPY002 is in Phase 2 development. If SKYLINE Part B (combination) data in Q3 2027 is positive, a Phase 3 program would follow. Assuming successful development, potential approval would be several years away, likely in the 2029-2031 timeframe.
Next catalyst
None dated

What to watchThe next hard catalyst for SPY002 is the SKYLINE Part B combination-therapy topline data expected in Q3 2027. Positive data would validate Spyre's combination strategy and could drive significant upside; negative data would undermine the entire platform thesis. The company also has SPY072 SKYWAY data and SKYLIGHT HS data as additional catalysts in late 2027/early 2028.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$99.04
T+0 close · Nov 3, 2026 · via day close
Latest settled
+7.86%
T+5 · $106.82 · next T+20 in 16d
Vs SPY
+8.77%
α at T+5
Latest observation
+4.16%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $99.04entry
  2. T+1 · 12d ago −2.47%α +1.94% · $96.59
  3. T+5 · 6d ago +7.86%α +8.77% · $106.82
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spyre Therapeutics reported Q3 2026 net loss of $96.1M ($0.94 per common share), wider than the $11.2M loss a year ago, driven by increased R&D spending. The company highlighted positive Phase 2 data for its IBD pipeline and plans to advance TL1A programs into pivotal HS studies, with $1.47B pro forma cash providing runway into H2 2029. The EPS of -$0.94 is below the consensus estimate of -$0.84, representing a miss.

Key Financial Metrics

EPS
−$0.94
est −$0.84 · -11.9%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Q3 2026 net loss of $96.1M vs $11.2M in Q3 2025
  • EPS of -$0.94 per common share vs consensus -$0.84
  • R&D expenses rose to $89.2M from $45.2M YoY
  • Pro forma cash $1.47B with runway into H2 2029
  • Positive Phase 2 data for SPY001, SPY002, SPY003 in IBD
  • SPY072 failed PsA and axSpA endpoints, will not advance in rheumatic disease
  • October 2026 public offering raised $378M net proceeds
  • SKYLINE Part B enrollment ahead of schedule, topline data expected Q3 2027

Financial Impact

Net loss widened by $84.9M YoY to $96.1M; EPS miss of $0.10 vs consensus

net lossepscash position

Risk Factors

  • SPY072 failed in PsA and axSpA, limiting rheumatic disease opportunity
  • R&D spend is accelerating with no near-term revenue
  • Dilution from October 2026 offering (11.8M shares added)
  • Clinical-stage biotech with no approved products

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3394730

Track record

36 reports on SYRE

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Viewing Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens in 7h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026